Particles
Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.
1. An embolic system including:
a syringe, a vial, or a combination thereof; and
embolic particles having an organic polymer backbone including a reaction product of a prepolymer solution including:
a poly(ethylene glycol) diacrylamide macromer, a poly(ethylene glycol) diacrylate macromer, a poly(ethylene glycol) dimethacrylate macromer, a poly(ethylene glycol) dimethacrylamide macromer, or a combination thereof; and
at least one monomer,
wherein the embolic particles have a diameter between about 50 μm and about 1,500 μm.
2. The embolic system of claim 1 , wherein the diameter is between about 400 μm and about 1,500 μm.
3. The embolic system of claim 1 , wherein the at least one monomer includes ionic groups.
4. The embolic system of claim 3 , wherein the monomer containing ionic groups is sodium acrylate.
5. The embolic system of claim 1 , wherein the prepolymer solution further includes a crosslinker.
6. The embolic system of claim 5 , wherein the crosslinker is biodegradable.
7. The embolic system of claim 6 , wherein the crosslinker has a structure:
wherein each n is independently 1-20;
wherein d, e, and f are each independently 1-20; or
8. The embolic system of claim 1 , wherein the embolic particles further include a visualization agent having a structure:
9. The embolic system of claim 1 , further including a flow diverting stent formed of a material having a pore size.
10. The embolic system of claim 9 , wherein the pore size is less than the diameter of the embolic particles.
11. A method of treatment, the method comprising:
delivering embolic particles through a delivery device to a treatment site jailed by a flow diverting stent,
wherein the embolic particles having an organic polymer backbone and are formed from a reaction product of a prepolymer solution including:
a poly(ethylene glycol) diacrylamide macromer, a poly(ethylene glycol) diacrylate macromer, a poly(ethylene glycol) dimethacrylate macromer, a poly(ethylene glycol) dimethacrylamide macromer, or a combination thereof; and
at least one monomer,
wherein the embolic particles have a diameter between about 50 μm and about 1,500 μm.
12. The method of claim 11 , wherein the delivering includes flushing the catheter with a non-solvent.
13. The method of claim 12 , wherein the non-solvent is a mineral oil, hexane, or water.
14. The method of claim 11 , wherein the delivery device is a catheter or a microcatheter.
15. The method of claim 11 , wherein the flow diverting stent includes a material having a pore size that is less than the diameter of the embolic particles.
16. The method of claim 11 , wherein the at least one monomer includes ionic groups.
17. The method of claim 11 , wherein the prepolymer solution further includes a crosslinker.
18. The method of claim 17 , wherein the crosslinker is biodegradable.
19. The method of claim 17 , wherein the crosslinker has a structure:
wherein each n is independently 1-20;
wherein d, e, f, and g are each independently 1-20; or
20. The method of claim 11 , wherein the embolic particles further include a visualization agent having a structure: